Shasqi
New accelerator entry · 2015-01-13 · the record
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug.
Shasqi is a Y Combinator company in the Winter 2015 batch. Its directory entry describes it as: Targeting Cancer with Click Chemistry. The founder listed is Jose M. Mejia Oneto (Founder/CEO) (Y Combinator directory entry, January 13, 2015).
Sell to companies like Shasqi? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2015-01-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Shasqi.
Free to see. No signup.
More on Shasqi and the records around it.
Same batch, Healthcare first.
Get an email when Shasqi changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Shasqi raises, hires or launches. No email unless you switch it on.
Watch Shasqi →Get the full cited report on Shasqi
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Shasqi: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ platform. Our technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two 'click', a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Shasqi: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Shasqi covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ShasqiYou get an alert in MentionFox the next time this company shows up.
If you're behind Shasqi: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Shasqi. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.

https://mentionfox.com/funding/yc-shasqi